μ and δ opioid agonists (University of Arizona)(μ and δ opioid agonists (University of Arizona)) - 药物靶点：δ opioid receptor x μ opioid receptor_在研适应症：痛觉过敏，疼痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

δ opioid receptor x μ opioid receptor

作用机制

δ opioid receptor激动剂(δ-阿片受体激动剂)、μ opioid receptor激动剂(μ-阿片受体激动剂)

治疗领域

神经系统疾病

在研适应症

痛觉过敏疼痛

非在研适应症-

原研机构

University of Arizona

在研机构

University of Arizona

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 μ and δ opioid agonists (University of Arizona) 相关的临床结果

登录后查看更多信息

100 项与 μ and δ opioid agonists (University of Arizona) 相关的转化医学

登录后查看更多信息

100 项与 μ and δ opioid agonists (University of Arizona) 相关的专利（医药）

登录后查看更多信息

1

项与 μ and δ opioid agonists (University of Arizona) 相关的文献（医药）

1991-04-01·Neuroscience Letters4区 · 医学

Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation

4区 · 医学

Article

作者: S. Bourgoin ; F. Cesselin ; J.J. Benoliel ; J.C. Legrand ; A. Mauborgne ; M. Hamon

Opioid-cholecystokinin (CCK) interactions at the spinal level were investigated by looking for possible modulations by various opioid agonists of the release of cholecystokinin-like material (CCKLM) from slices of the dorsal zone of the rat lumbar enlargement. K(+)-evoked CCKLM overflow was reduced by 0.1-10 microM of the mu agonist DAGO or 10 nM to 3 microM of the delta agonist DTLET. By contrast, at a higer concentration (10 microM), the latter drug as well as morphine enhanced CCKLM overflow. Although inactive alone, the kappa opioid agonist U 50488 H (1 microM) prevented the inhibitory effect of DAGO without affecting that of DTLET. These data suggest that an opioid acting through the stimulation of mu, delta and kappa receptors (such as morphine) should produce a net increase in the spinal release of CCK.

100 项与 μ and δ opioid agonists (University of Arizona) 相关的药物交易

登录后查看更多信息